Liquid biopsy for monitoring anaplastic lymphoma kinase inhibitors in non-small cell lung cancer: two cases compared

Mariangela Manicone, Maria Chiara Scaini, Maria Grazia Rodriquenz, Antonella Facchinetti, Alfredo Tartarone, Michele Aieta, Rita Zamarchi, Elisabetta Rossi

Research output: Contribution to journalReview article

Abstract

Three to seven percent of non-small cell lung cancer (NSCLC) patients show anaplastic lymphoma kinase (ALK)-translocation and could be treated with ALK-inhibitors. However, under crizotinib, a first-generation ALK-inhibitor, patients develop drug resistance after a median of 12 months. To overcome crizotinib resistance, several next-generation ALK inhibitors have been developed. In NSCLC, liquid biopsy allowed important improvements in the detection of the epidermal growth factor receptor (EGFR) mutation. The ability of liquid biopsy to detect oncogenic gene/protein fusions is a newly investigated field, and is not routinely applied yet. We here present two NSCLC patients, both rearranged for echinoderm microtubule associated-protein like 4-anaplastic lymphoma kinase (EML4-ALK) and treated accordingly, who differed in the clinical outcome. We analyzed the predictive value of the liquid biopsy components, namely epithelial cellular adhesion molecule (EpCAM)+ circulating tumor cells (CTCs), EpCAM low/neg CTCs, EML4-ALK rearranged CTCs, and cell-free mRNA (cfmRNA), during ALK-inhibitors treatment. This analysis showed a potential association between the liquid biopsy biomarkers, patients' outcome and response to treatment, thus suggesting their combined use in the clinical practice, as proposed here. This approach would allow longitudinal monitoring and consequent identification of putative drug-resistance mechanisms, in the light of improving high-risk patient management.

Original languageEnglish
Pages (from-to)S1391-S1396
JournalJournal of Thoracic Disease
Volume9
Issue numberSuppl 13
DOIs
Publication statusPublished - Oct 2017

Fingerprint

Non-Small Cell Lung Carcinoma
Biopsy
Circulating Neoplastic Cells
Drug Resistance
Gene Fusion
Risk Management
anaplastic lymphoma kinase
Epidermal Growth Factor Receptor
Biomarkers
Messenger RNA
Mutation
Therapeutics
Proteins

Keywords

  • Journal Article
  • Review

Cite this

Liquid biopsy for monitoring anaplastic lymphoma kinase inhibitors in non-small cell lung cancer : two cases compared. / Manicone, Mariangela; Scaini, Maria Chiara; Rodriquenz, Maria Grazia; Facchinetti, Antonella; Tartarone, Alfredo; Aieta, Michele; Zamarchi, Rita; Rossi, Elisabetta.

In: Journal of Thoracic Disease, Vol. 9, No. Suppl 13, 10.2017, p. S1391-S1396.

Research output: Contribution to journalReview article

@article{d60c6a7dcf004bc78d018e724582a96a,
title = "Liquid biopsy for monitoring anaplastic lymphoma kinase inhibitors in non-small cell lung cancer: two cases compared",
abstract = "Three to seven percent of non-small cell lung cancer (NSCLC) patients show anaplastic lymphoma kinase (ALK)-translocation and could be treated with ALK-inhibitors. However, under crizotinib, a first-generation ALK-inhibitor, patients develop drug resistance after a median of 12 months. To overcome crizotinib resistance, several next-generation ALK inhibitors have been developed. In NSCLC, liquid biopsy allowed important improvements in the detection of the epidermal growth factor receptor (EGFR) mutation. The ability of liquid biopsy to detect oncogenic gene/protein fusions is a newly investigated field, and is not routinely applied yet. We here present two NSCLC patients, both rearranged for echinoderm microtubule associated-protein like 4-anaplastic lymphoma kinase (EML4-ALK) and treated accordingly, who differed in the clinical outcome. We analyzed the predictive value of the liquid biopsy components, namely epithelial cellular adhesion molecule (EpCAM)+ circulating tumor cells (CTCs), EpCAM low/neg CTCs, EML4-ALK rearranged CTCs, and cell-free mRNA (cfmRNA), during ALK-inhibitors treatment. This analysis showed a potential association between the liquid biopsy biomarkers, patients' outcome and response to treatment, thus suggesting their combined use in the clinical practice, as proposed here. This approach would allow longitudinal monitoring and consequent identification of putative drug-resistance mechanisms, in the light of improving high-risk patient management.",
keywords = "Journal Article, Review",
author = "Mariangela Manicone and Scaini, {Maria Chiara} and Rodriquenz, {Maria Grazia} and Antonella Facchinetti and Alfredo Tartarone and Michele Aieta and Rita Zamarchi and Elisabetta Rossi",
year = "2017",
month = "10",
doi = "10.21037/jtd.2017.08.151",
language = "English",
volume = "9",
pages = "S1391--S1396",
journal = "Journal of Thoracic Disease",
issn = "2072-1439",
publisher = "AME Publishing Company",
number = "Suppl 13",

}

TY - JOUR

T1 - Liquid biopsy for monitoring anaplastic lymphoma kinase inhibitors in non-small cell lung cancer

T2 - two cases compared

AU - Manicone, Mariangela

AU - Scaini, Maria Chiara

AU - Rodriquenz, Maria Grazia

AU - Facchinetti, Antonella

AU - Tartarone, Alfredo

AU - Aieta, Michele

AU - Zamarchi, Rita

AU - Rossi, Elisabetta

PY - 2017/10

Y1 - 2017/10

N2 - Three to seven percent of non-small cell lung cancer (NSCLC) patients show anaplastic lymphoma kinase (ALK)-translocation and could be treated with ALK-inhibitors. However, under crizotinib, a first-generation ALK-inhibitor, patients develop drug resistance after a median of 12 months. To overcome crizotinib resistance, several next-generation ALK inhibitors have been developed. In NSCLC, liquid biopsy allowed important improvements in the detection of the epidermal growth factor receptor (EGFR) mutation. The ability of liquid biopsy to detect oncogenic gene/protein fusions is a newly investigated field, and is not routinely applied yet. We here present two NSCLC patients, both rearranged for echinoderm microtubule associated-protein like 4-anaplastic lymphoma kinase (EML4-ALK) and treated accordingly, who differed in the clinical outcome. We analyzed the predictive value of the liquid biopsy components, namely epithelial cellular adhesion molecule (EpCAM)+ circulating tumor cells (CTCs), EpCAM low/neg CTCs, EML4-ALK rearranged CTCs, and cell-free mRNA (cfmRNA), during ALK-inhibitors treatment. This analysis showed a potential association between the liquid biopsy biomarkers, patients' outcome and response to treatment, thus suggesting their combined use in the clinical practice, as proposed here. This approach would allow longitudinal monitoring and consequent identification of putative drug-resistance mechanisms, in the light of improving high-risk patient management.

AB - Three to seven percent of non-small cell lung cancer (NSCLC) patients show anaplastic lymphoma kinase (ALK)-translocation and could be treated with ALK-inhibitors. However, under crizotinib, a first-generation ALK-inhibitor, patients develop drug resistance after a median of 12 months. To overcome crizotinib resistance, several next-generation ALK inhibitors have been developed. In NSCLC, liquid biopsy allowed important improvements in the detection of the epidermal growth factor receptor (EGFR) mutation. The ability of liquid biopsy to detect oncogenic gene/protein fusions is a newly investigated field, and is not routinely applied yet. We here present two NSCLC patients, both rearranged for echinoderm microtubule associated-protein like 4-anaplastic lymphoma kinase (EML4-ALK) and treated accordingly, who differed in the clinical outcome. We analyzed the predictive value of the liquid biopsy components, namely epithelial cellular adhesion molecule (EpCAM)+ circulating tumor cells (CTCs), EpCAM low/neg CTCs, EML4-ALK rearranged CTCs, and cell-free mRNA (cfmRNA), during ALK-inhibitors treatment. This analysis showed a potential association between the liquid biopsy biomarkers, patients' outcome and response to treatment, thus suggesting their combined use in the clinical practice, as proposed here. This approach would allow longitudinal monitoring and consequent identification of putative drug-resistance mechanisms, in the light of improving high-risk patient management.

KW - Journal Article

KW - Review

U2 - 10.21037/jtd.2017.08.151

DO - 10.21037/jtd.2017.08.151

M3 - Review article

C2 - 29184678

VL - 9

SP - S1391-S1396

JO - Journal of Thoracic Disease

JF - Journal of Thoracic Disease

SN - 2072-1439

IS - Suppl 13

ER -